WS Velasquez

Lymphoma Recurrence 5 Years or Later Following Diffuse Large B-Cell Lymphoma: Clinical Characteristics and Outcome

Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin

Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: Clinical relevance in 71 patients

p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time

Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis.

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis [see comments]

Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma

Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma

Interleukin-10 and the Interleukin-10 Receptor

Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with an intensive epirubicin-containing regimen

Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma

Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma

Risk classification as the basis for clinical staging of diffuse large- cell lymphoma derived from 10-year survival data

Risk classification as the basis for clinical staging of diffuse large- cell lymphoma derived from 10-year survival data